should sunitinib still be used in the treatment of metstatic kidney cancer?
Published 6 years ago • 3.2K plays • Length 3:09Download video MP4
Download video MP3
Similar videos
-
5:18
are combination therapies the future of renal cell carcinoma treatment?
-
0:53
unanswered questions in the management of clear cell rcc
-
8:11
implications of using adjuvant sorafenib and sunitinib in unfavourable renal carcinoma
-
0:55
the emerging continuum of care in metastatic kidney cancer in the second-line and beyond
-
5:16
potential new treatments in renal cell carcinoma
-
1:18
using radiotherapy to manage oligometastatic kidney cancer
-
5:11
current treatment landscape for kidney cancer
-
4:15
the unmet needs of kidney cancer treatment
-
0:48
will immunotherapy take over the treatment landscape of patients high-risk renal cell carcinoma?
-
2:16
the agents at the forefront of kidney cancer treatment
-
7:34
frontline sunitinib compared to everolimus in metastatic renal cell carcinoma
-
6:57
dosing schedule of sunitinib in renal cell carcinoma
-
13:25
who is your ideal sunitinib patient? camillo porta, m.d.
-
1:51
inmunosun-sogug trial: sunitinib second line metastatic rcc
-
1:59
key objectives in kidney cancer: treatment sequencing & refining clinical endpoints
-
1:52
efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma
-
1:25
dr. tannir on the combination of sunitinib and temsirolimus for metastatic renal cell carcinoma
-
2:23
s-trac phase iii trial of sunitinib as adjuvant therapy in high-risk renal cell cancer patients
-
1:46
clinical trials in kidney cancer to look out for